Cardiac Biomarkers Companies-Strategic Expansion Initiatives, Market Entry and Expansion Strategies, Cross-border Expansion, Patent Fencing and Market Trends Analysis

Top Companies in the Cardiac Biomarkers Market

The global cardiac biomarkers market size is calculated at USD 21.27 billion in 2024, grew to USD 24.39 billion in 2025, and is projected to reach around USD 83.54 billion by 2034. The market is expanding at a CAGR of 14.66% between 2024 and 2034.

Abbott Laboratories, BioMérieux SA, Bio-Rad Laboratories, Inc., Creative Diagnostics, Danaher Corporation, F. Hoffmann-La Roche, Mindray, PerkinElmer, Quidel Corporation, Randox Laboratories, Ltd., Siemens Healthineers and Thermo Fisher Scientific.

Latest Announcements by Industry Leaders

Professor Damian Corrigan, Principal Investigator and Director of the Center for Advanced Measurement Research and Health Translation, Strathclyde, announced that they are working on a new technology to develop a rapid, low-cost sensor to detect heart attack victims more quickly. He stated that cardiac biomarkers can support an early and accurate diagnosis that will empower paramedics, community healthcare practitioners, and first responders to make the best decisions for delivering healthcare to patients and help save lives.

Recent Developments in the Cardiac Biomarkers Market

• In October 2024, researchers from Johns Hopkins University developed a new blood test using biophotonics or laser lights to detect blood biomarkers for faster analysis of a heart attack. The tool can measure CK-MB, myoglobin, and troponin I within minutes using ultra-low sample volumes.
• In October 2024, researchers from the MemorialCare Saddleback Medical Center found that higher levels of IgM anti-PC protected the women against CVD, and low levels were associated with both atherosclerosis and heart attack.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com | +1 804 441 9344